×

Research and Markets: Triple Analysis: Lung Cancer, Angiogenesis and Antibodies

DUBLIN, Nov 12, 2010 (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com/research/ca0b67/triple_analysis_l) has announced the addition of the "Triple Analysis: Lung Cancer, Angiogenesis and Antibodies" report to their offering.

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report: Part I: Lung Cancer The lung cancer report part includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). This report part extensively analyses 182 identified targets of lung cancer drugs, organized into 173 drug target strategies, and assesses them in lung cancer.

This part is based on the following publication: Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning Part II: Angiogenesis The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications. This part is based on the following publication: Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline.

Part III: Antibodies The antibody report part comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. This report part extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target strategies, and assesses them in 69 different cancer indications. This part is based on the following publication: Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place? The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies pipeline and portfolio planning (PPP) in cancer by: Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drugs properties Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities Supporting development of integrative molecule, pathway and disease area strategies Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered: Part I: Lung Cancer Part II: Angiogenesis Part III: Antibodies For more information visit http://www.researchandmarkets.com/research/ca0b67/triple_analysis_l SOURCE: Research and Markets Ltd.

CONTACT: Research and Markets Laura Wood, Senior Manager U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 press@researchandmarkets.com Copyright Business Wire 2010 -0- INDUSTRY KEYWORD: Health

Oncology

Pharmaceutical